TL;DR
Turn your wind-down time into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A November 6 MedPage Today opinion article argues that Democrats’ gains in the 2026 midterms create an opportunity to pursue healthcare priorities, including reversing Medicaid cuts and restoring Affordable Care Act premium subsidies. Those proposals are not enacted policy: funding, Senate procedure, President Trump’s veto power and the new Congress’s strategy remain unresolved.
A November 6 MedPage Today opinion article says Democrats have an opportunity to pursue healthcare priorities after the November 3, 2026, midterm elections, but warns that funding needs, procedural hurdles and possible presidential vetoes could limit what they can accomplish. The article identifies reversing Medicaid cuts and restoring Affordable Care Act premium subsidies as potential 2027 priorities; neither is described as enacted or agreed policy.
Author Steven Grossman argues that healthcare was among voters’ concerns in the midterms and that Democrats will need to deliver concrete results during the next two years. He cautions that electoral gains do not by themselves settle which proposals the party will pursue or whether they can pass Congress.
Grossman expects little healthcare legislation during the outgoing Congress’s lame-duck session, which runs until the new Congress is sworn in on January 3, 2027. He says legislation and nominations in that period generally require broad bipartisan support, urgency and enough time to clear procedural hurdles.
For 2027, the article describes several possible approaches: holding investigations into the administration’s policies, passing bills that President Donald Trump could veto, attaching policy provisions to must-pass legislation, or seeking compromises. Grossman points to the next FDA user-fee reauthorization as a potential vehicle for other provisions, and says a proposal called the Clinical Trial Modernization Act could be considered for inclusion. He notes that the reauthorization must become law by September 30 and ideally would be completed by June or July.
Funding Could Define Democrats’ Health Agenda
The proposals Grossman highlights would affect major federal health programs, but the article presents them as political possibilities, not commitments or legislative outcomes. Reversing Medicaid cuts and restoring ACA premium subsidies would require Congress to agree on policy and, as the article stresses, identify funding.
Grossman says Democrats could use budget reconciliation, which can allow a bill to pass the Senate with 51 votes, rather than the usual 60-vote threshold for most legislation. But that route does not remove the challenge of paying for the proposals. The source says Democrats would need to find $1.2 trillion over 10 years; it does not provide a detailed breakdown of that figure or specify the exact proposals and spending period to which it applies.
The stakes also extend to negotiations with the White House. If Democrats pass measures Trump opposes, he could veto them; attaching provisions to must-pass bills or negotiating could offer other routes, but each would require agreement on the details. The article does not establish which strategy party leaders will choose.
Popular right now
De'Longhi Stilosa Compact Manual Espresso Machine with Milk Frother
Dyson V15 Detect Cordless Vacuum
Samsung 75-Inch Class The Frame QLED 4K Art TV (LS03HE, 2026)
As an affiliate, we earn on qualifying purchases.
The Lame-Duck Session Comes First
The immediate legislative period is the lame-duck session between the election and the new Congress’s January 3, 2027, start. Grossman expects lawmakers to focus on appropriations and other high-priority matters and predicts little healthcare action. That is his assessment, not a confirmed schedule or a guarantee that no health legislation will move.
The author also raises questions about Health and Human Services leadership and Senate confirmations. He predicts that HHS Secretary Robert F. Kennedy Jr. could face hostile hearings under Democratic control of health committees and speculates that Kennedy might resign. He also argues that FDA commissioner nominee Heidi Overton is unlikely to be confirmed, particularly once the new Congress begins. These are Grossman’s forecasts; the source does not report that either official has resigned or that a nomination has been rejected.
Grossman notes that nominations left pending when the current Congress ends expire, requiring the White House to start again in the next Congress. He says a nominee could be changed, and that the administration could use a renewed nomination to preserve Kyle Diamantas as acting FDA commissioner. These personnel scenarios are predictions and possibilities outlined in the opinion article, not confirmed decisions.
“Democrats must deliver.”
— Steven Grossman, writing in MedPage Today
Policy Plans And Leadership Remain Open
The article does not say what healthcare bills Democrats will formally introduce, whether party leaders have settled on a strategy, or whether any proposal has enough support to pass. It also does not give a detailed financing plan for the $1.2 trillion over 10 years that Grossman says would be needed.
Several forecasts in the piece remain uncertain: whether Kennedy will leave HHS, whether Overton will be nominated again, and whether an FDA user-fee bill will carry other policy provisions. No confirmed resignation, new nomination, committee hearing schedule or agreement with the White House is provided. The source is an opinion analysis, so its predictions should not be read as official plans or settled outcomes.
Congressional Decisions Begin In January
The new Congress is scheduled to convene on January 3, 2027. Its early choices will show whether Democrats pursue investigations, legislation, negotiations with Trump, or a combination of those approaches. Any proposals to change Medicaid or ACA subsidies would still need to move through the legislative process and address their cost.
Grossman identifies the next FDA user-fee reauthorization as a possible legislative vehicle, with a statutory deadline of September 30 and an ideal completion target of June or July. Whether lawmakers attach measures such as the Clinical Trial Modernization Act, and whether the administration and Congress reach an agreement, remain to be seen.
Key Questions
What healthcare priorities does the article say Democrats may pursue?
Grossman identifies reversing Medicaid cuts and restoring ACA premium subsidies as possible priorities for 2027. The article does not say that either proposal has been introduced or approved.
When does the new Congress begin?
The new Congress is scheduled to be sworn in on January 3, 2027. The outgoing Congress meets in a lame-duck session before then.
How could Democrats try to pass healthcare policy?
The article lists investigations, bills that could face a presidential veto, provisions attached to must-pass legislation, and negotiated compromises. Grossman says the party’s actual strategy has not yet been decided.
What remains uncertain about the proposed healthcare changes?
The legislation, funding plan, congressional support and White House response are all unresolved in the source. The article also offers predictions about HHS and FDA leadership, but reports no confirmed resignation or nomination outcome.
Source: medpagetoday.com
